☆ 4.1 Article

Impact of institutional interventions on the rate of paclitaxel hypersensitivity reactions

JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2023)

Related references

Note: Only part of the references are listed.

Article Allergy

Hypersensitivity Reactions to Platinum Agents and Taxanes

Lulu R. Tsao et al.

Summary: Hypersensitivity reactions to chemotherapy agents pose a serious challenge in treating patients with preferred or first-line therapies. Allergic reactions through an immunologic mechanism have been established for platinum and taxane agents, and drug desensitization has been proven to be an effective method for safe reintroduction of both chemotherapeutic agents.

CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2022)

Add to Collection

Review Oncology

Do Steroids Matter? A Retrospective Review of Premedication for Taxane Chemotherapy and Hypersensitivity Reactions

Olivia M. Lansinger et al.

Summary: This study reviewed the pattern of steroid premedication in patients who received paclitaxel or docetaxel at Stanford Cancer Institute between January 2010 and June 2020. The results showed that neither dexamethasone dose nor route correlated with subsequent hypersensitivity reactions, suggesting routine use of lower doses of dexamethasone for premedication may be preferable.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy

Napa Parinyanitikul et al.

SUPPORTIVE CARE IN CANCER (2018)

Add to Collection

Article Oncology

Meta-analysis of the effects of oral and intravenous dexamethasone premedication in the prevention of paclitaxel-induced allergic reactions

Fu-Chao Chen et al.

ONCOTARGET (2017)

Add to Collection

Article Allergy

Management of Hypersensitivity Reactions to Taxanes

Matthieu Picard

IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA (2017)

Add to Collection

Article Oncology

Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines

S. Rosello et al.

ANNALS OF ONCOLOGY (2017)

Add to Collection

Article Allergy

Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions

Matthieu Picard et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)

Add to Collection

Article Oncology

Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction

Michael J. Berger et al.

SUPPORTIVE CARE IN CANCER (2015)

Add to Collection

Article Allergy

The diagnosis and management of anaphylaxis practice parameter: 2010 Update

Phillip Lieberman et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)

Add to Collection

Article Oncology

Oral premedication for the prevention of hypersensitivity reactions to paclitaxel

Jamal Zidan et al.

MEDICAL ONCOLOGY (2008)

Add to Collection

Article Biotechnology & Applied Microbiology

Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL(R)-free formulation of paclitaxel

Thomas E. Stinchcombe

NANOMEDICINE (2007)

Add to Collection

Article Oncology

Management and preparedness for infusion and hypersensitivity reactions

Heinz-Josef Lenz

ONCOLOGIST (2007)

Add to Collection

Article Medicine, General & Internal

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Alan Sandler et al.

NEW ENGLAND JOURNAL OF MEDICINE (2006)

Add to Collection

Article Oncology

Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy

T Sendo et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)

Add to Collection

Article Oncology

Premedication strategy for weekly paclitaxel

J Quock et al.

CANCER INVESTIGATION (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.